Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 107, Issue 1, Pages 15-22Publisher
WILEY
DOI: 10.1002/jso.23192
Keywords
pancreatic cancer; pancreatic ductal adenocarcinoma; biomarkers; predictive markers; prognostic markers
Ask authors/readers for more resources
Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens. J. Surg. Oncol. 2013;107:1522. (c) 2012 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available